Jiangsu Sinopep-Allsino Biopharmaceutical (688076.SH) subsidiary passes US FDA on-site inspection.

Jiangsu Sinopep-Allsino Biopharmaceutical (688076.SH) announced that its controlling subsidiary, Hangzhou Noetinuo Bio-Pharmaceutical Technology Co., Ltd. (referred to as "Noetinuohe"), underwent an on-site inspection by the Food and Drug Administration (FDA) of the United States from October 28, 2024 to November 1, 2024 for cGMP (current Good Manufacturing Practice) compliance. Recently, Noetinuohe received the on-site inspection report issued by the FDA, confirming the successful completion of this cGMP on-site inspection.